Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PYGL | P06737 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 3/20 | 0.34 |
| ▸ | CTSS | P25774 | 3/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KLK7 | P49862 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4796322 | 0.86 | RAB9A (0.34) | RAB9ANPC1POLBPKMPYGL | |
| SCHEMBL6705838 | 0.84 | CTSS (0.43) | RAB9ANPC1POLBSMN1; SMN2CTSL | |
| SCHEMBL4796328 | 0.82 | CTSL (0.40) | RAB9ANPC1POLBCTSLCTSS | |
| SCHEMBL4798324 | 0.77 | ALDH1A1 (0.36) | RAB9ANPC1ALDH1A1CTSLCTSS | |
| SCHEMBL4798977 | 0.76 | RAB9A (0.40) | RAB9ANPC1POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL4796443 | 0.73 | KMT2A (0.39) | RAB9ANPC1POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL4798327 | 0.72 | METAP2 (0.42) | ALDH1A1TSHRCTSLCTSSCTSK | |
| SCHEMBL6685915 | 0.72 | RAB9A (0.35) | RAB9ANPC1POLBPKMSMN1; SMN2 | |
| SCHEMBL4798980 | 0.72 | NPC1 (0.41) | RAB9ANPC1CTSLCTSSCTSK | |
| SCHEMBL4796545 | 0.71 | PSMB8 (0.36) | RAB9ANPC1SMN1; SMN2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248887-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248887-A1 | Inhibitors of cathepsin S | CTSS, CTSB, CTSZ | RAB9A 905/4885NPC1 82/4885POLB 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.